Education
About Us
Working with TipRanks
Follow Us
Haemonetics (HAE)
:HAE
Earnings Data
Report Date
Aug 12, 2025TBA Not Confirmed
Period Ending
2026 (Q1)Consensus EPS Forecast
1.01Last Year’s EPS
1.02Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 9.43%
|Next Earnings Date:Aug 12, 2025
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with strong revenue growth in the hospital segment and significant margin expansion, but it also faced challenges with the decline in Plasma revenue due to CSL transition and ongoing issues in China's market.Company Guidance
During the Q4 2025 earnings call, Haemonetics Corporation provided extensive guidance for fiscal year 2026, highlighting several key metrics and projections. The company anticipates total organic revenue growth of 6% to 9%, excluding CSL, driven by strong performance in its Plasma and Hospital businesses. In the Hospital segment, revenue growth is projected to be between 8% and 11%, with significant contributions expected from both Interventional Technologies and Blood Management Technologies. Specifically, Vascular Closure revenue is forecasted to grow double-digit, supported by an 8.6% growth in addressable access sites in electrophysiology (EP) in the U.S. The company expects continued double-digit growth in Hemostasis Management and Transfusion Management within Blood Management Technologies. In Plasma, excluding CSL, an organic growth of 11% to 14% is anticipated, primarily fueled by U.S. share gains and technology adoption. The adjusted operating margin is projected to improve by 200 to 300 basis points, reaching 26% to 27%, with adjusted earnings per diluted share expected to be in the range of $4.70 to $5. Additionally, the guidance includes considerations for a $0.20 adjusted EPS impact from tariffs, and the adjusted tax rate is expected to increase to approximately 24.5%. The company forecasts free cash flow in fiscal 2026 to be between $160 million and $200 million, with a conversion ratio exceeding 70%.Strong Revenue Growth in Hospital Segment
Hospital revenue grew 12% in Q4 and 24% in fiscal 2025 on a reported basis, with organic growth of 9% and 12%, respectively.
Impressive Margin Expansion
Adjusted gross margin increased by 620 basis points in Q4 to 60.2% and by 300 basis points for fiscal 2025 to 57.4%.
Significant Plasma Revenue Growth Ex-CSL
Excluding CSL, Plasma revenue grew 11% in Q4 and 5% for fiscal 2025.
Share Buyback Program
Executed a $150 million share buyback, repurchasing approximately 2.4 million shares, and announced a new $500 million share repurchase program.
Enhanced Profitability and Earnings Growth
Fourth quarter adjusted net income was $61.6 million, up 34%, while adjusted earnings per diluted share was $1.24, up 39%.
---
HAE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
HAE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $64.25 | $68.01 | +5.85% |
Feb 06, 2025 | $71.24 | $62.99 | -11.58% |
Nov 07, 2024 | $78.16 | $86.53 | +10.71% |
Aug 08, 2024 | $85.72 | $76.43 | -10.84% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Haemonetics (HAE) report earnings?
Haemonetics (HAE) is schdueled to report earning on Aug 12, 2025, TBA Not Confirmed.
What is Haemonetics (HAE) earnings time?
Haemonetics (HAE) earnings time is at Aug 12, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HAE EPS forecast?
HAE EPS forecast for the fiscal quarter 2026 (Q1) is 1.01.
---